Adverse effects: general adverse events (UKU Average change score) · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events (partial loss of movement, algodystrophic syndrome) · patients with trigger finger
It is very uncertain whether open surgery changes adverse events (partial loss of movement, algodystrophic syndrome) compared with steroid injection plus hyaluronic acid injection guided by ultrasound (very low certainty).
1 finding from 1 review
Adverse events: Measured as number of patients with adverse events · Mechanically ventilated adults in the intensive care unit
1 finding from 1 review
Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
Perazine showed no clear difference in overall tolerability Leaving the study early due to adverse events compared with other antipsychotics (low certainty).
1 finding from 1 review
Adverse events assessed during catheter dwell or on product removal · people with arterial catheter dressing and securement
Integrated securement dressings showed no clear difference in adverse events assessed during catheter dwell or on product removal compared with standard polyurethane (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Any adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Adverse events number of participants hospitalised during the trial · children with cystic fibrosis
Summary of findings: Zinc supplementation showed no clear difference in adverse events number of participants hospitalised during the trial compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events or adverse events Death due to methadone use · individuals dependent on illicit opiates
1 finding from 1 review
Serious adverse events or complications of treatment — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Adverse events: General‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
1 finding from 1 review
Weight gain · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in adverse events: Weight gain Number of participants with weight gain compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Adverse events ‐ gastrointestinal reactions Diagnosed by clinicians · patients with oesophageal cancer
It is very uncertain whether active cancer therapy combined with TCM changes adverse events ‐ gastrointestinal reactions Diagnosed by clinicians compared with active cancer therapy (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with the treatment of cocaine dependence
Amantidine showed no clear difference in adverse events as N of participants with at least one adverse event compared with antidepressants (low certainty).
1 finding from 1 review